Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-15
    E.g., 2018-07-15

Articles

8922 items
2:37 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Addiction Cell culture and mouse studies identified a peptide-based antagonist of the OPRD1/MOR heterodimer that could help treat opiate withdrawal. Chemical synthesis and testing in cell-based competitive binding and activity assays of conjugates linking OPRD1...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Otologic

INDICATION: Hereditary deafness Patient samples and mouse studies suggest that inhibiting REST or HDAC could help treat hearing loss associated with gain-of-function REST mutations. In a family with inherited progressive hearing loss, sequencing of a...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies identified an inhibitor of M. tuberculosis cytochrome bc1 that could help treat tuberculosis (TB). Screening of small molecule library in M. tuberculosis culture and chemical synthesis of analogs of...
2:36 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Blistering disorder Patient sample and cell culture studies suggest the generic antibiotic gentamicin could help treat Herlitz junctional epidermolysis bullosa, a blistering disorder caused by loss-of-function mutations in LAMB3. In patient-derived junctional epidermolysis cells and...
2:35 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum insulin...
2:35 PM, Jul 10, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
10:54 AM, Jun 28, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro, cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two compounds that...
10:53 AM, Jun 28, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Cancer; gastric cancer; lung cancer; brain cancer In vitro, cell culture and mouse studies identified four methylquinazoline-based PI3K inhibitors that could help treat cancer. Chemical synthesis of methylquinazoline analogs and in vitro enzyme activity assays...
10:52 AM, Jun 28, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest agonizing GPR139 could help treat alcohol addiction. In a rat model of alcohol dependence, oral administration or intracerebral injection into the habenula of a tool compound GPR139 agonist decreased alcohol intake...
10:52 AM, Jun 28, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease; transplant; endocrine/metabolic

INDICATION: Multiple sclerosis (MS); graft-versus-host disease (GvHD); diabetes Cell culture and mouse studies suggest that IL-2 complexed with an anti-IL-2 mAb could help treat GvHD, MS, Type I diabetes and other autoimmune diseases. In human peripheral...

Pages